Trial Profile
Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse.
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Tanespimycin (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms BMS-TIME-1; TIME-1
- Sponsors Bristol-Myers Squibb; Kosan Biosciences
- 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trials Database record
- 31 Mar 2022 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 19 Mar 2010 Planned end date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov.